Global Venous Thromboembolism Market – Industry Trends and Forecast to 2029

Global Venous Thromboembolism Market, By Product (Non-Segmented Pneumatic Compression Pumps, Segmented Pneumatic Compression Pumps without Gradient, Segmented Pneumatic Compression Pumps with Calibrated Gradient, Upper Pneumatic Compression Sleeves, Lower Pneumatic Compression Sleeves, Permanent Inferior Vena Cava Filters, Retrievable Inferior Vena Cava Filters, Embolectomy Balloon Catheters, Percutaneous Thrombectomy Devices, Catheter-Directed Thrombolysis (CDT) Devices), Type (Deep Vein Thrombosis, Pulmonary Embolism, Others), Treatment (Anti-Clotting Medications, Mechanical Devices, Thrombolytic Therapy, Others), End-Users (Hospitals, Homecare, Speciality Centres, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Venous Thrombophilia Market Analysis and Size

The global venous thromboembolism market is expected to witness significant growth during the forecast period. There is increasing pervasiveness of cardiovascular diseases (CVD) and cancer due to adoption of smoking, increasing obesity rate, alcohol, lack of physical activity and consumption of high cholesterol food. The deep venous thrombosis segment is projected to account for more than 3/5th of venous thromboembolism treatment sales by 2022. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global venous thromboembolism market in the forecast period 2022-2029. The expected CAGR of global venous thromboembolism market is tend to be around 8.50% in the mentioned forecast period. The market was valued at USD 950 million in 2021, and it would grow upto USD 1824.57 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Venous thromboembolism is a type of condition in which a blood clot forms most often in the deep veins of the leg, groin or arm and travels in the circulation, lodging in the lungs. Both deep vein thrombosis and pulmonary embolism altogether form venous thromboembolism, which is a dangerous, potentially deadly medical condition. It is of great importance to the healthcare sector and thus is expected to rise high in the forecast period.

Venous Thrombophilia Market Scope and Segmentation

Global Thrombophilia Market Dynamics

Drivers

• Increase in Geriatric Population

The geriatric population is expected to increase the patient population globally, which boots the global venous thromboembolism market in the forecast period. According to the WHO, the global elderly population is expected to reach around 2 billion by 2050 from 617 million in 2015. This boost the market growth.

• Rising Awareness Towards The Disease

Numerous organizations are taking initiatives to raise awareness about VTE worldwide. Few organizations, in collaboration with the CDC, are joining the ‘Stop the Clot, Spread the Word’ campaign to spread awareness all over the country about blood clots. Many such initiatives will positively impact knowledge about disease diagnosis and treatment alternatives, thus boosting the market value during the forecast period.

Opportunities

• Growing Number of Orthopedic Procedures

Growing number of surgical procedures has encouraged the adoption of compression devices for DVT prophylaxis. Surgeries that include orthopedic procedures cause long immobility and thus, there is a greater probability of DVT development. Therefore, patients are recommended to use compression devices post-procedure to limit the risk. Thus, this will create more opportunities for the market growth.

• Emergence of Several Treatment Methods

Venous thromboembolism is a potentially dangerous condition and if it is not treated at suitable time, it may lead to complications and death. According to Centres for Disease Control and Prevention (CDC), about 60,000-100,000 people in the U.S. die due to venous thromboembolism. Also, blood clots are mainly managed by drug therapy. Although, sometimes, patient may require surgical intervention and mechanical devices to manage and treat the condition more successfully. Thus, with key market players introducing novel devices, the end-users will have wider range of treatment options, thus presenting huge growth opportunities during the forecast period. This creates more opportunity in the market.

Restraints/Challenges

• Lack of Skilled Professionals

Lack of trained professionals who are unaware of the knowledge of the treatment methods for this disease could curb the growth of the global venous thromboembolism market over a forecast period.

• High Cost

The huge expenditure of the treatment methods such as different anti-thrombotic medications, thrombolytic therapy hamper the market growth.

This global venous thromboembolism market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global venous thromboembolism market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments:

• In May 2019, Pfizer, Inc. received the U.S. FDA approval for FRAGMIN, which is a dalteparin sodium to lessen the recurrence of venous thromboembolism (VTE) in pediatric patients, aged 1 month and above.
• In July 2019, Bayer AG and Johnson and Johnson’s JNJ subsidiary announced novel results from phase III EINSTEIN-Jr study about children suffering from venous thromboembolism (VTE).
• In June 2021, Janssen Pharmaceuticals, Inc, announced receiving Food and Drug Administration approval for its latest products XARELTO (rivaroxaban) for the treatment of two indications: deep venous thrombosis and pulmonary embolism. This will support the company to strengthen its footprint in the market.

Global Venous Thromboembolism Market Scope

The global venous thromboembolism market is segmented on the basis of type, drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Non-Segmented Pneumatic Compression Pumps
• Segmented Pneumatic Compression Pumps without Gradient
• Segmented Pneumatic Compression Pumps with Calibrated Gradient
• Upper Pneumatic Compression Sleeves
• Lower Pneumatic Compression Sleeves
• Permanent Inferior Vena Cava Filters
• Retrievable Inferior Vena Cava Filters
• Embolectomy Balloon Catheters
• Percutaneous Thrombectomy Devices
• Catheter-Directed Thrombolysis (CDT) Devices

Type

• Deep Vein Thrombosis
• Pulmonary Embolism
• Others

Treatment

• Anti-Clotting Medications
•  Mechanical Devices
• Thrombolytic Therapy
• Others

End-Users

• Hospitals
• Homecare
• Speciality Centres
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Venous Thromboembolism Market Regional Analysis/Insights

The global venous thromboembolism market is analysed and market size insights and trends are provided by type, drugs, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global venous thromboembolism market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is expected to have the highest market growth due to the presence of key manufacture of the product and increased prevalence of thromboembolism in this region.

Asia-Pacific dominates the market due to increased prevalence of embolism and increasing geriatric population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Venous Thromboembolism Market Share Analysis

The global venous thromboembolism market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global venous thromboembolism market.

Key players operating in the global venous thromboembolism market include:

• Pfizer Inc (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Mylan N.V. (U.S.)
• Aspen Holdings (U.S.)
• Changzhaou Qianhong Bio-pharma Co., ltd. (China)
• Fresenius Kabi AG (Germany)
• Hebei Changshan Biochemical Pharmaceutical Co. Ltd. (China)
• Hikma Pharmaceuticals PLC (U.K.)
• Novartis AG (Switzerland)
• Janssen Global Services, LLC (U.S.)